Middle East respiratory syndrome coronavirus ORF4b protein inhibits type i interferon production through both cytoplasmic and nuclear targets

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Yang, Yang ^a,b   Ye, Fei ^a   Zhu, Na ^a   Wang, Wenling ^a   Deng, Yao ^a   Zhao, Zhengdong ^a   Tan, Wenjie ^a  

^a BEIJING HOSPITAL   (China)

^b SHENZHEN THIRD PEOPLE S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; DDX58 PROTEIN, HUMAN; I KAPPA B KINASE; IFIH1 PROTEIN, HUMAN; INTERFERON INDUCED HELICASE C DOMAIN CONTAINING PROTEIN 1; INTERFERON REGULATORY FACTOR 3; INTERFERON REGULATORY FACTOR 7; IRF3 PROTEIN, HUMAN; IRF7 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; RETINOIC ACID INDUCIBLE PROTEIN I; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TBK1 PROTEIN, HUMAN; VIRAL PROTEIN; VISA PROTEIN, HUMAN;

CELL NUCLEUS; CYTOPLASM; GENETICS; HELA CELL LINE; HOST PATHOGEN INTERACTION; HUMAN; METABOLISM; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; PATHOGENICITY; PHOSPHORYLATION; VIROLOGY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CELL NUCLEUS; CYTOPLASM; DEAD BOX PROTEIN 58; HELA CELLS; HOST-PATHOGEN INTERACTIONS; HUMANS; I-KAPPA B KINASE; INTERFERON REGULATORY FACTOR-3; INTERFERON REGULATORY FACTOR-7; INTERFERON-BETA; INTERFERON-INDUCED HELICASE, IFIH1; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; VIRAL PROTEINS;

EID: 84949257684     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep17554     Document Type: Article

References (61)

1. Zaki, A. M., van Boheemen, S., Bestebroer, T. M., Osterhaus, A. D. & Fouchier,R. A. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. The New England journal of medicine 367, 1814-1820 (2012).
2. World Health Organization. Novel coronavirus infection - update. (2015), http://www.who.int/csr/don/12-october-2015-merssaudi- arabia/en/. [Accessed October 12, 2015].
3. Butler, D. Clusters of coronavirus cases put scientists on alert. Nature 492, 166-167 (2012).
4. Breban, R., Riou, J. & Fontanet, A. Interhuman transmissibility of Middle East respiratory syndrome coronavirus: estimation of pandemic risk. Lancet 382, 694-699 (2013).
5. Hui, D. S., Perlman, S. & Zumla, A. Spread of MERS to South Korea and China. Lancet Respir Med 3, 509-510 (2015).
6. Peiris, J. S., Yuen, K. Y., Osterhaus, A. D. & Sthr, K. The severe acute respiratory syndrome. The New England journal of medicine 349, 2431-2441 (2003).
7. Drosten, C. et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. The New England journal of medicine 348, 1967-1976 (2003).
8. Garca-Sastre, A. & Biron, C. A. Type 1 interferons and the virus-host relationship a lesson in dtente. Science 312, 879-882 (2006).
9. Randall, R. E. & Goodbourn, S. Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J. Gen. Virol. 89, 1-47 (2008).
10. Bermingham, A. et al. Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East, September 2012. Euro Surveill. 17, 20290 (2012).
11. Zielecki, F. et al. Human cell tropism and innate immune system interactions of human respiratory coronavirus EMC compared to those of severe acute respiratory syndrome coronavirus. J. Virol. 87, 5300-5304 (2013).
12. Chan, R. W. et al. Tropism of and innate immune responses to the novel human betacoronavirus lineage C virus in human ex vivo respiratory organ cultures. J. Virol. 87, 6604-6614 (2013).
13. Falzarano, D. et al. Inhibition of novel β coronavirus replication by a combination of interferon-α 2b and ribavirin. Sci. Rep. 3, 1686 (2013).
14. de Wilde, A. H. et al. MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A orinterferon-α treatment. J. Gen. Virol. 94, 1749-1760 (2013).
15. Yang, Y. et al. The structural and accessory proteins M, ORF 4a, ORF 4b, and ORF 5 of Middle East respiratory syndrome coronavirus (MERS-CoV) are potent interferon antagonists. Protein & Cell 4, 951-961 (2013).
16. Niemeyer, D. et al. Middle East respiratory syndrome coronavirus accessory protein 4a is a type I interferon antagonist. J. Virol. 87, 12489-12495 (2013).
17. Matthews, K. L., Coleman, C. M., van der Meer, Y., Snijder, E. J. & Frieman, M. B. The ORF4b-encoded accessory proteins of Middle East respiratory syndrome coronavirus and two related bat coronaviruses localize to the nucleus and inhibit innate immune signalling. J. Gen. Virol. 9, 874-882 (2014).
18. Siu, K. L. et al. Middle East Respiratory Syndrome Coronavirus 4a Protein Is a Double-Stranded RNA-Binding Protein That Suppresses PACT-Induced Activation of RIG-I and MDA5 in the Innate Antiviral Response. J. Virol. 88, 4866-4876 (2014).
19. Yang, X. et al. Proteolytic processing, deubiquitinase and interferon antagonist activities of Middle East respiratory syndrome coronavirus papain-like protease. J. Gen. Virol. 95, 614-626 (2014).
20. Bailey-Elkin, B. A. et al. Crystal Structure of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Papain-like Protease Bound to Ubiquitin Facilitates Targeted Disruption of Deubiquitinating Activity to Demonstrate Its Role in Innate Immune Suppression. J. Biol. Chem. 289, 34667-34682 (2014).
21. Takeuchi, O. & Akira, S. MDA5/RIG-I and virus recognition. Current opinion in virology 20, 17-22 (2008).
22. Seth, R. B., Sun, L., Ea, C. K. & Chen, Z. J. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF3. Cell 122, 669-682 (2005).
23. Meylan, E. et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 437, 1167-1172 (2005).
24. Kawai, T. et al. IPS-1, an adaptor triggering RIG-I and Mda5-mediated type I interferon induction. Nat. Immunol. 6, 981-988 (2005).
25. Scobey, T. et al. Reverse genetics with a full-length infectious cDNA of the Middle East respiratory syndrome coronavirus. Proc. Natl. Acad. Sci. USA 110, 16157-16162 (2013).
26. Almazán, F. et al. Engineering a replication-competent, propagation-defective Middle East respiratory syndrome coronavirus as a vaccine candidate. mBio 4, e00650-13, doi: 10.1128/mBio.00650-13 (2013).
27. Khan, S. et al. Over-expression of severe acute respiratory syndrome coronavirus 3b protein induces both apoptosis and necrosis in Vero E6 cells. Virus Research 122, 20-27 (2006).
28. Childs, K. S., Andrejeva, J., Randall, R. E. & Goodbourn, S. Mechanism of MDA-5 inhibition by paramyxovirus V proteins. J. Virol. 83, 1465-1473 (2009).
29. Prins, K. C., Cardenas, W. B. & Basler, C. F. Ebola virus protein VP35 impairs the function of interferon regulatory factoractivating kinases IKKepsilon and TBK-1. J. Virol. 83, 3069-3077 (2009).
30. Taylor, K. E. & Mossman, K. L. Recent advances in understanding viral evasion of type I interferon. Immunology 138, 190-197 (2013).
31. Totura, A. L. & Baric, R. S. SARS coronavirus pathogenesis: host innate immune responses and viral antagonism of interferon. Current opinion in virology 2, 264-275 (2012).
32. Kopecky-Bromberg, S. A., Martinez-Sobrido, L., Frieman, M., Baric, R. A. & Palese, P. Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and nucleocapsid proteins function as interferon antagonists. J. Virol. 81, 548-557 (2007).
33. Devaraj, S. G. et al. Regulation of IRF-3-dependent innate immunity by the papain-like protease domain of the severe acute respiratory syndrome coronavirus. J. Biol. Chem. 282, 32208-32221 (2007).
34. Frieman, M., Ratia, K., Johnston, R. E., Mesecar, A. D. & Baric, R. S. Severe acute respiratory syndrome coronavirus papain-like protease ubiquitinlike domain and catalytic domain regulate antagonism of IRF3 and NFkappaB signaling. J. Virol. 83, 6689-6705 (2009).
35. Clementz, M. A. et al. Deubiquitinating and interferon antagonism activities of coronavirus papain-like proteases. J. Virol. 84, 4619-4629 (2010).
36. Chen, X. et al. SARS coronavirus papain-like protease inhibits the type I interferon signaling pathway through interaction with the STING-TRAF3-TBK1 complex. Protein & Cell 5, 369-381 (2014).
37. Wathelet, M. G., Orr, M., Frieman, M. B. & Baric, R. S. Severe acute respiratory syndrome coronavirus evades antiviral signaling: role of nsp1 and rational design of an attenuated strain. J. Virol. 81, 11620-11633 (2007).
38. Narayanan, K. et al. Severe acute respiratory syndrome coronavirus nsp1 suppresses host gene expression, including that of type I interferon, in infected cells. J. Virol. 82, 4471-4479 (2008).
39. Zust, R. et al. Coronavirus non-structural protein 1 is a major pathogenicity factor: implications for the rational design of coronavirus vaccines. PLoS Pathog. 3, e109 (2007).
40. Siu, K. L. et al. Severe acute respiratory syndrome coronavirus M protein inhibits type I interferon production by impeding the formation of TRAF3.TANK.TBK1/IKKepsilon complex. J. Biol. Chem. 284, 16202-16209 (2009).
41. Shi, C. S. et al. SARS-coronavirus open reading frame-9b suppresses innate immunity by targeting mitochondria and the MAVS/ TRAF3/TRAF6 signalosome. J. Immunol. 193, 3080-3089 (2014).
42. Kaukinen, P., Sillanp, M., Nousiainen, L., Melin, K. & Julkunen, I. Hepatitis C virus NS2 protease inhibits host cell antiviral response by inhibiting IKKε and TBK1 functions. J. Med. Virol. 85, 71-82 (2013).
43. Lu, L. L., Puri, M., Horvath, C. M. & Sen, G. C. Select paramyxoviral V proteins inhibit IRF3 activation by acting as alternative substrates for inhibitor of kappaB kinase epsilon (IKKe)/TBK1. J. Biol. Chem. 283, 14269-14276 (2008).
44. Brzzka, K., Finke, S. & Conzelmann, K. K. Identification of the rabies alpha/beta interferon antagonist: phosphoprotein P interferes with phosphorylation of interferon regulatory factor 3. J. Virol. 79, 7673-7681 (2005).
45. Ren, J. et al. A novel mechanism for the inhibition of interferon regulatory factor-3-dependent gene expression by human respiratory syncytial virus NS1 protein. J. Gen. Virol. 92, 2153-2159 (2011).
46. Le May, N. et al. A SAP30 complex inhibits IFN-beta expression in Rift Valley fever virus infected cells. PLoS Pathog. 4, e13 (2008).
47. Rodriguez, A., Prez-González, A. & Nieto, A. Influenza virus infection causes specific degradation of the largest subunit of cellular RNA polymerase II. J. Virol. 81, 5315-5324 (2007).
48. Llompart, C. M., Nieto, A. & Rodriguez-Frandsen, A. Specific residues of PB2 and PA influenza virus polymerase subunits confer the ability for RNA polymerase II degradation and virus pathogenicity in mice. J. Virol. 88, 3455-3463 (2014).
49. Rodriguez, A. et al. Attenuated strains of influenza A viruses do not induce degradation of RNA polymerase II. J. Virol. 83, 11166-11174 (2009).
50. Dai-Ju, J. Q., Li, L., Johnson, L. A. & Sandri-Goldin, R. M. ICP27 interacts with the C-terminal domain of RNA polymerase II and facilitates its recruitment to herpes simplex virus 1 transcription sites, where it undergoes proteasomal degradation during infection. J. Virol. 80, 3567-3581 (2006).
51. Fraser, K. A. & Rice, S. A. Herpes simplex virus immediate-early protein ICP22 triggers loss of serine 2-phosphorylated RNA polymerase II. J. Virol. 81, 5091-5101 (2007).
52. Lonard, V. H., Kohl, A., Hart, T. J. & Elliott, R. M. Interaction of Bunyamwera Orthobunyavirus NSs protein with mediator protein MED8-a mechanism for inhibiting the interferon response. J. Virol. 80, 9667-9675 (2006).
53. Zaborowska, J. et al. Herpes Simplex Virus 1 (HSV-1) ICP22 protein directly interacts with cyclin-dependent kinase (CDK)9 to inhibit RNA polymerase II transcription elongation. PLoS One. 9, e107654, doi: 10.1371/journal.pone.0107654. eCollection (2014).
54. Wolff, T. & Ludwig, S. Influenza viruses control the vertebrate type I interferon system: factors, mechanisms, and consequences. J Interferon Cytokine Res. 29, 549-557 (2009).
55. Engel, D. A. The influenza virus NS1 protein as a therapeutic target. Antiviral Res. 99, 409-416 (2013).
56. Gack, M. U. et al. Influenza A virus NS1 targets the ubiquitin ligase TRIM25 to evade recognition by the host viral RNA sensor RIG-I. Cell Host Microbe. 5, 439-449 (2009).
57. Noah, D. L., Twu, K. Y. & Krug, R. M. Cellular antiviral responses against influenza A virus are countered at the posttranscriptional level by the viral NS1A protein via its binding to a cellular protein required for the 3′ end processing of cellular pre-mRNAS. Virology. 307, 386-395 (2003).
58. Satterly, N. et al. Influenza virus targets the mRNA export machinery and the nuclear pore complex. Proc. Natl. Acad. Sci. USA 104, 1853-1858 (2007).
59. Kochs, G., Garca-Sastre, A. & Martnez-Sobrido, L. Multiple anti-interferon actions of the influenza A virus NS1 protein. J Virol. 81, 7011-7021 (2007).
60. Wang, B. et al. Enterovirus 71 protease 2Apro targets MAVS to inhibit anti-viral type I interferon responses. PLoS Pathog. 9, e1003231 (2013).
61. Lei, X. et al. The 3C protein of enterobirus 71 inhibits retinoid acid-inducible gene I-mediated interferon regulatory factor 3 activation and type I interron responses. J. Virol. 84, 8051-8061 (2010).